Astec LifeSciences Grants 1,142 Stock Options Under ESOP 2012 to Eligible Employee

Astec LifeSciences Limited has announced the grant of 1,142 stock options to an eligible employee under its Employee Stock Option Plan 2012 (ESOP 2012). The grant was approved by the company's Nomination and Remuneration Committee on April 30, 2026, in compliance with regulatory requirements.

Stock Option Grant Details

The company has provided comprehensive details regarding the stock option grant structure and terms:

Parameter: Details Number of Options: 1,142 stock options Exercise Price: Rs.10/- per option Face Value per Share: Rs.10/- Vesting Period: 3 years Exercise Window: 1 month from vesting date

Each stock option entitles the holder to apply for one equity share of the company with a face value of Rs.10/-. The exercise price has been set at Rs.10/- per option, matching the face value of the underlying shares.

Regulatory Compliance and Framework

The stock option grant has been structured in accordance with multiple regulatory frameworks to ensure full compliance. The grant falls under the provisions of the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. Additionally, the announcement has been made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Vesting and Exercise Terms

The granted options follow a structured vesting schedule designed to align employee interests with long-term company performance. The options will vest over a period of 3 years, providing a gradual release of benefits to the eligible employee. Once vested, the options must be exercised within 1 month from the date of vesting, though the Nomination and Remuneration Committee retains the authority to determine alternative exercise periods if deemed appropriate.

Corporate Communication

Astec LifeSciences has ensured transparent communication of this development through multiple channels. The company has formally notified both BSE Limited and National Stock Exchange of India Limited about the stock option grant. The information has also been uploaded on the company's official website at www.godrejastec.com , ensuring accessibility for all stakeholders and maintaining compliance with disclosure requirements.

Astec LifeSciences Limited has published its audited financial results for the quarter and financial year ended March 31, 2026, following approval by the Board of Directors on April 27, 2026. The results were disclosed through newspaper publications on April 28, 2026, in Business Standard (English) and Mumbai Lakshdeep (Marathi), as required under SEBI regulations.

Financial Performance Overview

The company's financial performance for FY26 showed mixed results with increased revenue but continued losses. Total income from operations reached ₹45,321.65 lakhs for the full year, representing growth from ₹38,693.22 lakhs in the previous financial year.

Metric FY26 (Audited) FY25 (Audited) Q4 FY26 Q3 FY26 Q4 FY25 Total Income from Operations (₹ lakhs) 45,321.65 38,693.22 16,125.62 12,553.55 12,031.82 Net Loss Before Tax (₹ lakhs) (7,890.58) (14,098.92) (790.01) (1,358.08) (1,566.10) Net Loss After Tax (₹ lakhs) (8,087.62) (13,471.17) (774.70) (1,568.53) (1,607.90) Total Comprehensive Loss (₹ lakhs) (8,041.45) (13,453.79) (753.67) (1,554.73) (1,631.94)

Capital Structure and Financial Position

The company's capital structure showed significant changes during the year, with equity share capital increasing to ₹2,228.22 lakhs from ₹1,961.14 lakhs in the previous year. Net worth improved substantially to ₹39,091.84 lakhs compared to ₹23,501.65 lakhs in FY25.

Parameter FY26 FY25 Change Equity Share Capital (₹ lakhs) 2,228.22 1,961.14 +267.08 Securities Premium Account (₹ lakhs) 29,502.82 6,139.18 +23,363.64 Net Worth (₹ lakhs) 39,091.84 23,501.65 +15,590.19 Outstanding Debt (₹ lakhs) 44,892.99 55,454.41 -10,561.42 Debt Equity Ratio 1.15 2.36 -1.21

Earnings Per Share and Key Ratios

The company reported negative earnings per share for both basic and diluted calculations. For FY26, the loss per share stood at ₹37.79 compared to ₹68.71 in the previous year, showing improvement despite continued losses.

Key Financial Ratios:

Debt Service Coverage Ratio: (0.01) for FY26 vs (1.15) for FY25

Interest Service Coverage Ratio: (0.04) for FY26 vs (1.48) for FY25

Capital Redemption Reserve: ₹0.30 lakhs (unchanged)

Regulatory Compliance

The financial results disclosure was made pursuant to Regulation 30 read with Schedule III and Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company secretary Tejashree Pradhan signed the compliance documents on April 28, 2026, ensuring proper regulatory adherence for the BSE-listed company with scrip code 533138.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.